Published online Sep 26, 2023. doi: 10.12998/wjcc.v11.i27.6407
Peer-review started: August 1, 2023
First decision: August 16, 2023
Revised: August 22, 2023
Accepted: August 29, 2023
Article in press: August 29, 2023
Published online: September 26, 2023
Processing time: 50 Days and 15.7 Hours
This study aimed to explore the relationship between serum thyroglobulin (Tg) and thyroid-stimulating hormone (TSH) levels and the risk of thyroid cancer in individuals undergoing thyroid nodule surgery. The primary objective was to ascertain whether these biomarkers could serve as predictive tools for thyroid cancer.
A retrospective analysis was conducted on clinical data and laboratory results from 130 patients who had undergone thyroid nodule surgery. Preoperative serum Tg and TSH levels were recorded. Histopathological examination determined thyroid cancer status during follow-up. Statistical methods were employed to evaluate the potential correlations.
Among the 130 patients studied, 60 were diagnosed with thyroid cancer. Statistical analysis revealed a significant positive correlation between serum Tg levels and thyroid cancer risk (P < 0.05), indicating higher Tg levels were linked to increased risk. However, no significant correlation was found between serum TSH levels and thyroid cancer risk (P > 0.05).
In the context of patients undergoing thyroid nodule surgery, serum Tg levels were observed to have a notable correlation with the risk of thyroid cancer, while serum TSH levels did not exhibit such a correlation. These findings underscore the potential of serum Tg levels as a valuable biomarker for assessing thyroid cancer risk in patients with thyroid nodules.
The study's findings provide valuable insights into the clinical utility of serum Tg levels as a predictive tool for thyroid cancer risk. Further research is warranted to validate these findings across larger and more diverse patient populations. Additionally, exploring other potential biomarkers and refining predictive models could enhance the accuracy of thyroid cancer risk assessment.
Given the prevalence of thyroid nodules and the challenge of distinguishing between benign and malignant cases, understanding the correlation between Tg and TSH levels and thyroid cancer risk is essential. Identifying reliable biomarkers could enhance early detection and improve patient outcomes.
Thyroid nodules are a common clinical concern, with some harboring the potential for malignancy. Detecting thyroid cancer accurately is crucial. Serum Tg and TSH levels have been suggested as potential indicators of thyroid cancer risk, prompting the need for a comprehensive investigation.